Latest On IVERIC bio, Inc (ISEE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-30 16:21 EST | News | Iveric bio, Still A 5+% Opportunity | N/A |  |
| 2023-05-23 13:53 EST | News | Bayer, Amgen looked at Iveric before agreeing to Astellas sale - report | N/A | |
| 2023-05-01 10:45 EST | News | IVERIC Bio jumps 18% on acquisition by Astellas Pharma | N/A | |
| 2023-04-30 23:01 EST | News | Astellas Pharma agrees to buy Iveric Bio for $5.9 billion | N/A | |
| 2023-03-23 20:31 EST | News | Iveric Bio: ACP Advances As GATHER Results Continue To Impress | N/A | |
| 2023-03-02 03:14 EST | News | IVERIC bio, Inc. (ISEE) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-01 12:27 EST | News | IVERIC bio GAAP EPS of -$0.47 misses by $0.10 | N/A | |
| 2023-03-01 12:27 EST | News | Iveric bio stock rises as drug helps cut risk of potential vision loss in trials | N/A | |
| 2023-02-28 21:36 EST | News | IVERIC bio Q4 2022 Earnings Preview | N/A | |
| 2023-02-17 04:21 EST | News | IVERIC bio stock +7% after FDA accepts NDA for Avacincaptad Pegol | N/A | |
| 2022-12-28 13:54 EST | News | IVERIC bio out-licenses gene therapy candidates for cash and stock | N/A | |
| 2022-12-07 14:54 EST | News | Iveric bio: Building Momentum Around Zimura, Rate Buy | N/A | |
| 2022-12-01 12:39 EST | News | Iveric bio stock slides on pricing upsized $300M stock offering | N/A | |
| 2022-11-30 19:09 EST | News | IVERIC launches $250M stock offering | N/A | |
| 2022-11-17 22:53 EST | News | IVERIC bio gets FDA breakthrough therapy designation for geographic atrophy treatment | N/A | |
| 2022-11-10 18:35 EST | News | Apellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA market | N/A | |
| 2022-11-04 21:33 EST | News | Iveric bio starts filing with FDA under rolling review for eye drug | N/A | |
| 2022-11-03 10:50 EST | News | IVERIC bio GAAP EPS of -$0.35 beats by $0.06 | N/A | |
| 2022-11-02 18:55 EST | News | IVERIC bio Q3 2022 Earnings Preview | N/A | |
| 2022-09-09 23:40 EST | News | Developing Transformative Therapies for Retinal Diseases | N/A | |
| 2022-09-07 19:56 EST | News | Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura | N/A | |
| 2022-09-07 03:17 EST | News | Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate | N/A | |
| 2022-09-06 10:21 EST | News | Iveric stock soars 41% as eye disorder drug Zimura meets main goal in phase 3 trial | N/A | |
| 2022-07-26 17:37 EST | News | IVERIC bio GAAP EPS of -$0.41 misses by $0.09 | N/A | |
| 2022-07-26 17:36 EST | News | IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-25 14:56 EST | News | IVERIC bio Q2 2022 Earnings Preview | N/A | |
| 2022-07-19 18:54 EST | News | Iveric Bio, NGM gain as Apellis wins priority review for GA candidate | N/A | |
| 2022-07-08 05:13 EST | News | Iveric Bio price target raised at Morgan Stanley ahead of clinical data in Q3 | N/A | |
| 2022-07-05 15:01 EST | News | Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura | N/A | |
| 2022-06-23 14:44 EST | News | IVERIC bio: A First Take | N/A | |
| 2022-06-08 20:43 EST | News | IVERIC Bio stock rises after BofA, Guggenheim initiate with buy ratings | N/A | |
| 2022-05-05 04:57 EST | News | IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-05 04:57 EST | News | Iveric wins Street high target at Stifel on new data for geographic atrophy candidate | N/A | |
| 2022-05-04 08:04 EST | News | IVERIC bio GAAP EPS of -$0.29 misses by $0.01 | N/A | |
| 2022-05-03 15:36 EST | News | IVERIC bio Q1 2022 Earnings Preview | N/A | |
| 2022-03-23 04:38 EST | News | Iveric Bio lands Buy rating from Jefferies Financial | N/A | |
| 2022-02-25 09:50 EST | News | IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-24 14:11 EST | News | IVERIC bio GAAP EPS of -$0.29 misses by $0.04 | N/A | |
| 2022-02-23 19:22 EST | News | IVERIC bio Q4 2021 Earnings Preview | N/A | |
| 2022-02-08 00:53 EST | News | Iveric Bio draws Bullish view at Morgan Stanley ahead of data from pivotal study | N/A | |
| 2022-02-02 20:18 EST | News | Iveric Bio grants inducement options to one newly hired employee | N/A | |
| 2021-12-01 03:27 EST | News | IVERIC (ISEE) Investor presentation - Slideshow | N/A | |
| 2021-11-24 00:13 EST | News | IVERIC bio (ISEE) Investor Presentation - Slideshow | N/A | |
| 2021-11-10 10:14 EST | News | IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-10 10:13 EST | News | IVERIC bio, Inc. 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-11-09 11:07 EST | News | IVERIC bio EPS beats by $0.06 | N/A | |
| 2021-11-08 13:36 EST | News | IVERIC bio Q3 2021 Earnings Preview | N/A | |
| 2021-10-22 13:39 EST | News | Iveric Bio falls ~8% amid announcement of $125M common stock offering | N/A | |
| 2021-10-22 13:38 EST | News | Iveric Bio prices upsized stock offering at $16.75 | N/A | |
| 2021-09-25 04:42 EST | News | Kadmon, Adagio top weekly healthcare gainers; Forte Biosciences and Humanigen trail | N/A | |
About IVERIC bio, Inc (ISEE):
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.
General
- Name IVERIC bio, Inc
- Symbol ISEE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 57
- Fiscal Year EndDecember
- IPO Date2013-09-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://ivericbio.com
View More
Valuation
- Price/Book (Most Recent Quarter) 3.15
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.04
- Next Year EPS Estimate -$0.93
- Next Quarter EPS Estimate -$0.25
- Return on Assets -32%
- Return on Equity -55%
- Earnings Per Share $1.53
- Revenue Per Share $0
- Gross Profit -62784000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 555.27 million
- EBITDA -58471000
- Analyst Target Price $13.33
- Book Value Per Share $2.13
View More
Share Statistics
- Shares Outstanding 90.14 million
- Shares Float 63.72 million
- % Held by Insiders 65%
- % Held by Institutions 92.4%
- Shares Short 4.6 million
- Shares Short Prior Month 6.03 million
- Short Ratio 7.04
- Short % of Float 6%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 1.6
- 52 Week High $7.98
- 52 Week Low $2.8
- 50 Day Moving Average 6.05
- 200 Day Moving Average 6.08
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
IVERIC bio, Inc (ISEE) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
IVERIC bio, Inc (ISEE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-03 | $N/A | -$0.27 | -$0.24 | -12.5% |
| 2020-09-30 | 2020-11-02 | $N/A | -$0.27 | -$0.21 | -31.71% |
| 2020-06-30 | 2020-08-05 | $N/A | -$0.32 | -$0.27 | -18.52% |
| 2020-03-31 | 2020-05-06 | $N/A | -$0.28 | -$0.34 | 17.65% |
| 2019-12-31 | 2020-02-27 | $N/A | -$0.39 | -$0.25 | -56% |
| 2019-09-30 | 2019-11-12 | $N/A | -$0.35 | ||
| 2019-06-30 | 2019-08-01 | $N/A | -$0.35 | ||
| 2019-03-31 | 2019-05-08 | $N/A | -$0.30 | -$0.41 | 26.65% |
| 2018-12-31 | 2019-02-26 | $N/A | -$0.53 | -$0.41 | -27.36% |
| 2018-09-30 | 2018-10-31 | $N/A | -$0.41 | -$0.43 | 5.31% |
| 2018-06-30 | 2018-08-01 | $N/A | -$0.37 | -$0.39 | 4.42% |
| 2018-03-31 | 2018-05-09 | $N/A | -$0.36 | -$0.40 | 10.49% |
| 2017-12-31 | 2018-02-27 | $N/A | -$0.26 | -$0.55 | 52.75% |
| 2017-09-30 | 2017-11-08 | $206.65 million | $5.25 | $4.34 | 20.95% |
| 2017-06-30 | 2017-07-26 | $1.66 million | -$0.62 | -$1.04 | 40.33% |
| 2017-03-31 | 2017-05-03 | $1.66 million | -$1.20 | -$1.31 | 8.22% |
| 2016-12-31 | 2017-02-28 | $5.32 million | -$1.86 | -$1.67 | -11.1% |
| 2016-09-30 | 2016-11-08 | -$1.71 | -$1.65 | -3.4% | |
| 2016-06-30 | 2016-08-03 | $28.2 million | -$0.85 | -$1.37 | 38.02% |
| 2016-03-31 | 2016-05-04 | $15.72 million | -$1.03 | -$1.39 | 26% |
| 2015-12-31 | 2016-02-24 | -$1.02 | -$1.28 | 20.2% | |
| 2015-09-30 | 2015-11-05 | $3.45 million | -$1.14 | -$1.05 | -8.57% |
| 2015-06-30 | 2015-08-05 | $1.6 million | -$1.08 | -$1.02 | -5.88% |
| 2015-03-31 | 2015-05-11 | $41.68 million | $0.22 | -$0.75 | 129.33% |
| 2014-12-31 | 2015-02-23 | $1.68 million | -$1.06 | -$0.57 | -85.96% |
| 2014-09-30 | 2014-11-11 | $39.58 million | $0.31 | -$0.62 | 150% |
| 2014-06-30 | 2014-08-06 | $N/A | -$1.57 | -$0.56 | -180.36% |
| 2014-03-31 | 2014-05-13 | $N/A | -$0.64 | -$0.67 | 4.48% |
| 2013-12-31 | 2014-02-27 | -$0.65 | -$0.50 | -30% | |
| 2013-09-30 | 2013-11-13 | $N/A | -$10.26 | -$1.19 | -762.18% |
IVERIC bio, Inc (ISEE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
IVERIC bio, Inc (ISEE) Chart:
IVERIC bio, Inc (ISEE) News:
Below you will find a list of latest news for IVERIC bio, Inc (ISEE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
IVERIC bio, Inc (ISEE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest ISEE Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 14 | $9.115 |
| Jun 13, 2022 7:59 PM EST | 81 | $9.12 |
| Jun 13, 2022 7:59 PM EST | 2 | $9.12 |
| Jun 13, 2022 7:59 PM EST | 5 | $9.12 |
| Jun 13, 2022 7:59 PM EST | 7 | $9.12 |
IVERIC bio, Inc (ISEE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000119380520000763/0001193805-20-000763-index.htm |
| 2018-08-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1410939/000000000018025062/0000000000-18-025062-index.htm |
| 2019-03-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1410939/000000000019004275/0000000000-19-004275-index.htm |
| 2020-08-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1410939/000000000020007320/0000000000-20-007320-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000091957419001707/0000919574-19-001707-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000093583619000110/0000935836-19-000110-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000093583620000114/0000935836-20-000114-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000103738919000123/0001037389-19-000123-index.htm |
| 2018-08-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1410939/000104746918005356/0001047469-18-005356-index.htm |
| 2019-11-12 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1410939/000104746919006217/0001047469-19-006217-index.htm |
| 2019-12-05 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1410939/000104746919006672/0001047469-19-006672-index.htm |
| 2019-12-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1410939/000104746919006724/0001047469-19-006724-index.htm |
| 2020-06-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1410939/000104746920003670/0001047469-20-003670-index.htm |
| 2020-06-19 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1410939/000104746920003735/0001047469-20-003735-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000108514620000769/0001085146-20-000769-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000109544920000018/0001095449-20-000018-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918043878/0001104659-18-043878-index.htm |
| 2018-07-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918044688/0001104659-18-044688-index.htm |
| 2018-07-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918044689/0001104659-18-044689-index.htm |
| 2018-07-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918044691/0001104659-18-044691-index.htm |
| 2018-08-13 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1410939/000110465918051535/0001104659-18-051535-index.htm |
| 2018-08-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000110465918053125/0001104659-18-053125-index.htm |
| 2018-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000110465918064869/0001104659-18-064869-index.htm |
| 2018-11-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000110465918067368/0001104659-18-067368-index.htm |
| 2018-12-14 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918073127/0001104659-18-073127-index.htm |
| 2018-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918073128/0001104659-18-073128-index.htm |
| 2018-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918073129/0001104659-18-073129-index.htm |
| 2018-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918073130/0001104659-18-073130-index.htm |
| 2018-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918073132/0001104659-18-073132-index.htm |
| 2018-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465918073133/0001104659-18-073133-index.htm |
| 2019-01-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000564/0001104659-19-000564-index.htm |
| 2019-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000569/0001104659-19-000569-index.htm |
| 2019-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000888/0001104659-19-000888-index.htm |
| 2019-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000893/0001104659-19-000893-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919001169/0001104659-19-001169-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919001170/0001104659-19-001170-index.htm |
| 2019-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919019738/0001104659-19-019738-index.htm |
| 2019-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919028906/0001104659-19-028906-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919030026/0001104659-19-030026-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919030028/0001104659-19-030028-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919030030/0001104659-19-030030-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919030032/0001104659-19-030032-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919030033/0001104659-19-030033-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919039283/0001104659-19-039283-index.htm |
| 2019-11-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919065146/0001104659-19-065146-index.htm |
| 2019-12-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000110465919071176/0001104659-19-071176-index.htm |
| 2019-12-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919071930/0001104659-19-071930-index.htm |
| 2019-12-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919071931/0001104659-19-071931-index.htm |
| 2019-12-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919071932/0001104659-19-071932-index.htm |
| 2019-12-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919071933/0001104659-19-071933-index.htm |
| 2019-12-16 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073025/0001104659-19-073025-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073112/0001104659-19-073112-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073113/0001104659-19-073113-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073115/0001104659-19-073115-index.htm |
| 2019-12-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073117/0001104659-19-073117-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920002077/0001104659-20-002077-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920002078/0001104659-20-002078-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000110465920021210/0001104659-20-021210-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000110465920021858/0001104659-20-021858-index.htm |
| 2020-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920043229/0001104659-20-043229-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920072339/0001104659-20-072339-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920072340/0001104659-20-072340-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920072341/0001104659-20-072341-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920072342/0001104659-20-072342-index.htm |
| 2020-06-16 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920073630/0001104659-20-073630-index.htm |
| 2020-06-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1410939/000110465920074170/0001104659-20-074170-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000110465920074175/0001104659-20-074175-index.htm |
| 2020-06-17 | S-3MEF | Registration adding securities to prior Form S-3 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1410939/000110465920074324/0001104659-20-074324-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000110465920075248/0001104659-20-075248-index.htm |
| 2020-06-24 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000110465920076161/0001104659-20-076161-index.htm |
| 2020-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920081362/0001104659-20-081362-index.htm |
| 2020-07-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920084574/0001104659-20-084574-index.htm |
| 2020-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000110465920084577/0001104659-20-084577-index.htm |
| 2020-08-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1410939/000110465920091544/0001104659-20-091544-index.htm |
| 2020-08-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1410939/000110465920093291/0001104659-20-093291-index.htm |
| 2020-08-14 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1410939/000110465920094807/0001104659-20-094807-index.htm |
| 2020-09-18 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1410939/000110465920106513/0001104659-20-106513-index.htm |
| 2018-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000114420418037833/0001144204-18-037833-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000114420419008090/0001144204-19-008090-index.htm |
| 2018-06-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000119312518189510/0001193125-18-189510-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000119312520030573/0001193125-20-030573-index.htm |
| 2020-10-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000119312520279958/0001193125-20-279958-index.htm |
| 2020-07-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000119380520000763/0001193805-20-000763-index.htm |
| 2018-07-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000120919118042364/0001209191-18-042364-index.htm |
| 2018-11-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000120919118057892/0001209191-18-057892-index.htm |
| 2019-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000120919119003905/0001209191-19-003905-index.htm |
| 2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1410939/000120919120038640/0001209191-20-038640-index.htm |
| 2020-06-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000121390020015977/0001213900-20-015977-index.htm |
| 2018-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000035/0001410939-18-000035-index.htm |
| 2018-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000039/0001410939-18-000039-index.htm |
| 2018-07-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000041/0001410939-18-000041-index.htm |
| 2018-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000044/0001410939-18-000044-index.htm |
| 2018-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000047/0001410939-18-000047-index.htm |
| 2018-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000049/0001410939-18-000049-index.htm |
| 2018-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000051/0001410939-18-000051-index.htm |
| 2018-11-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000056/0001410939-18-000056-index.htm |
| 2018-11-02 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000057/0001410939-18-000057-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000059/0001410939-18-000059-index.htm |
| 2018-12-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093918000062/0001410939-18-000062-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000003/0001410939-19-000003-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000004/0001410939-19-000004-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000008/0001410939-19-000008-index.htm |
| 2019-02-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000012/0001410939-19-000012-index.htm |
| 2019-02-28 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000014/0001410939-19-000014-index.htm |
| 2019-03-01 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000016/0001410939-19-000016-index.htm |
| 2019-04-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000018/0001410939-19-000018-index.htm |
| 2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000021/0001410939-19-000021-index.htm |
| 2019-04-18 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000023/0001410939-19-000023-index.htm |
| 2019-04-23 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000027/0001410939-19-000027-index.htm |
| 2019-04-23 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000028/0001410939-19-000028-index.htm |
| 2019-04-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000030/0001410939-19-000030-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000034/0001410939-19-000034-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000036/0001410939-19-000036-index.htm |
| 2019-05-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000038/0001410939-19-000038-index.htm |
| 2019-07-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000040/0001410939-19-000040-index.htm |
| 2019-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000043/0001410939-19-000043-index.htm |
| 2019-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000045/0001410939-19-000045-index.htm |
| 2019-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000048/0001410939-19-000048-index.htm |
| 2019-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000050/0001410939-19-000050-index.htm |
| 2019-10-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000053/0001410939-19-000053-index.htm |
| 2019-10-31 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000057/0001410939-19-000057-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000061/0001410939-19-000061-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093919000063/0001410939-19-000063-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000003/0001410939-20-000003-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000005/0001410939-20-000005-index.htm |
| 2020-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000009/0001410939-20-000009-index.htm |
| 2020-02-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000011/0001410939-20-000011-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000015/0001410939-20-000015-index.htm |
| 2020-04-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000017/0001410939-20-000017-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000019/0001410939-20-000019-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000023/0001410939-20-000023-index.htm |
| 2020-05-07 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000024/0001410939-20-000024-index.htm |
| 2020-06-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000026/0001410939-20-000026-index.htm |
| 2020-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000028/0001410939-20-000028-index.htm |
| 2020-07-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000032/0001410939-20-000032-index.htm |
| 2020-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000034/0001410939-20-000034-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000037/0001410939-20-000037-index.htm |
| 2020-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000040/0001410939-20-000040-index.htm |
| 2020-11-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1410939/000141093920000044/0001410939-20-000044-index.htm |
| 2019-12-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000143774919024266/0001437749-19-024266-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000143774920002692/0001437749-20-002692-index.htm |
| 2020-06-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000149315220012080/0001493152-20-012080-index.htm |
| 2018-10-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000156761918003709/0001567619-18-003709-index.htm |
| 2019-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000156761919002451/0001567619-19-002451-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1410939/000156761920002637/0001567619-20-002637-index.htm |
| 2018-08-15 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1410939/999999999518002115/9999999995-18-002115-index.htm |
| 2019-04-25 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1410939/999999999519000827/9999999995-19-000827-index.htm |
| 2020-08-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1410939/999999999520002145/9999999995-20-002145-index.htm |
| 2020-09-24 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1410939/999999999520002557/9999999995-20-002557-index.htm |
| 2018-08-10 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1410939/999999999718007238/9999999997-18-007238-index.htm |
| 2018-11-02 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1410939/999999999718008924/9999999997-18-008924-index.htm |
| 2019-07-09 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1410939/999999999719006079/9999999997-19-006079-index.htm |
| 2020-02-06 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1410939/999999999720000564/9999999997-20-000564-index.htm |
| 2020-02-20 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1410939/999999999720000853/9999999997-20-000853-index.htm |
IVERIC bio, Inc (ISEE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of IVERIC bio, Inc (ISEE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 65%Institutional Ownership: 9240%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-11-15 | GLENN SBLENDORIO | President and CEO | Buy | 15,000.00 | 3.12 | 46,851.00 | 114,354.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919065146/0001104659-19-065146-index.htm |
| 2018-07-01 | David Francis Carroll | SVP, CFO and Treasurer | Buy | 7,500.00 | 11,716.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465918043878/0001104659-18-043878-index.htm | ||
| 2019-07-02 | David Francis Carroll | SVP, CFO and Treasurer | Sell | 2,773.00 | 1.25 | 3,466.25 | 13,707.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919039283/0001104659-19-039283-index.htm |
| 2019-07-01 | David Francis Carroll | SVP, CFO and Treasurer | Buy | 7,500.00 | 16,480.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919039283/0001104659-19-039283-index.htm | ||
| 2019-12-10 | GLENN SBLENDORIO | President and CEO | Buy | 62,500.00 | 4.00 | 250,000.00 | 176,854.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919071931/0001104659-19-071931-index.htm |
| 2019-12-12 | GLENN SBLENDORIO | President and CEO | Buy | 22,950.00 | 199,804.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073115/0001104659-19-073115-index.htm | ||
| 2020-04-01 | GLENN SBLENDORIO | President and CEO | Buy | 18,750.00 | 225,061.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465920043229/0001104659-20-043229-index.htm | ||
| 2019-12-12 | David Francis Carroll | SVP, CFO and Treasurer | Buy | 12,500.00 | 26,207.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073117/0001104659-19-073117-index.htm | ||
| 2019-01-03 | Keith Westby | SVP & COO | Sell | 342.00 | 1.24 | 424.08 | 32,205.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000893/0001104659-19-000893-index.htm |
| 2019-01-02 | Keith Westby | SVP & COO | Buy | 781.00 | 32,547.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000893/0001104659-19-000893-index.htm | ||
| 2019-01-07 | Keith Westby | SVP & COO | Sell | 299.00 | 1.30 | 388.70 | 32,606.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919001170/0001104659-19-001170-index.htm |
| 2019-01-04 | Keith Westby | SVP & COO | Buy | 700.00 | 32,905.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919001170/0001104659-19-001170-index.htm | ||
| 2020-07-01 | David Francis Carroll | SVP, CFO and Treasurer | Buy | 7,500.00 | 33,707.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465920081362/0001104659-20-081362-index.htm | ||
| 2019-12-13 | Keith Westby | SVP & COO | Sell | 4,530.00 | 6.60 | 29,898.00 | 40,576.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073112/0001104659-19-073112-index.htm |
| 2019-01-03 | DAVID R GUYER | Executive Chairman | Sell | 3,637.00 | 1.24 | 4,509.88 | 40,773.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000888/0001104659-19-000888-index.htm |
| 2020-01-06 | Keith Westby | SVP & COO | Sell | 293.00 | 8.07 | 2,364.51 | 40,983.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465920002078/0001104659-20-002078-index.htm |
| 2020-01-04 | Keith Westby | SVP & COO | Buy | 700.00 | 41,276.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465920002078/0001104659-20-002078-index.htm | ||
| 2019-01-07 | DAVID R GUYER | Executive Chairman | Sell | 3,859.00 | 1.30 | 5,016.70 | 43,164.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919001169/0001104659-19-001169-index.htm |
| 2019-01-02 | DAVID R GUYER | Executive Chairman | Buy | 5,750.00 | 44,410.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919000888/0001104659-19-000888-index.htm | ||
| 2019-12-12 | Keith Westby | SVP & COO | Buy | 12,500.00 | 45,106.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073112/0001104659-19-073112-index.htm | ||
| 2019-01-04 | DAVID R GUYER | Executive Chairman | Buy | 6,250.00 | 47,023.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919001169/0001104659-19-001169-index.htm | ||
| 2019-12-13 | DAVID R GUYER | Executive Chairman | Sell | 9,275.00 | 6.60 | 61,215.00 | 51,089.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073113/0001104659-19-073113-index.htm |
| 2020-01-06 | DAVID R GUYER | Executive Chairman | Sell | 3,367.00 | 8.07 | 27,171.69 | 53,972.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465920002077/0001104659-20-002077-index.htm |
| 2020-01-04 | DAVID R GUYER | Executive Chairman | Buy | 6,250.00 | 57,339.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465920002077/0001104659-20-002077-index.htm | ||
| 2019-12-12 | DAVID R GUYER | Executive Chairman | Buy | 17,200.00 | 60,364.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919073113/0001104659-19-073113-index.htm | ||
| 2019-04-02 | GLENN SBLENDORIO | President and CEO | Sell | 6,914.00 | 1.43 | 9,887.02 | 68,105.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919019738/0001104659-19-019738-index.htm |
| 2019-04-01 | GLENN SBLENDORIO | President and CEO | Buy | 18,750.00 | 75,019.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919019738/0001104659-19-019738-index.htm | ||
| 2018-07-02 | David Francis Carroll | SVP, CFO and Treasurer | Sell | 2,736.00 | 2.68 | 7,332.48 | 8,980.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465918043878/0001104659-18-043878-index.htm |
| 2019-05-10 | GLENN SBLENDORIO | President and CEO | Buy | 25,000.00 | 1.48 | 37,000.00 | 93,105.00 | https://www.sec.gov/Archives/edgar/data/1410939/000110465919028906/0001104659-19-028906-index.htm |